Biomimetic hypoxia-triggered RNAi nanomedicine for synergistically mediating chemo/radiotherapy of glioblastoma-Reference-Cited by-同舟云学术

Biomimetic hypoxia-triggered RNAi nanomedicine for synergistically mediating chemo/radiotherapy of glioblastoma

Published:2023-02-01 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Wang Zhen¹,Tang Xianglong¹,Zhao Mengjie¹,Zhang Yiding¹,Xiao Yong¹,Liu Yuyang¹,Qian Chunfa¹,Xie Yandong¹,Liu Yong¹,Zou Yuanjie¹,Yang Kun¹,Liu Hongyi¹

Affiliation:

1. the Affiliated Brain Hospital with Nanjing Medical University, Fourth Clinical College of Nanjing Medical University

Abstract

Abstract Background: Although RNA interference (RNAi) therapy has emerged as a potential tool in cancer therapeutics, the application of RNAi to glioblastoma (GBM) remains a hurdle. Herein, to improve the therapeutic effect of RNAi on GBM, a cancer cell membrane (CCM)-disguised hypoxia-triggered RNAi nanomedicine was developed for short interfering RNA (siRNA) delivery to sensitize cells to chemotherapy and radiotherapy. Our synthesized CCM-disguised RNAi nanomedicine showed prolonged blood circulation, high BBB transcytosis and specific accumulation in GBM sites via homotypic recognition. Disruption and effective anti-GBM agents were triggered in the hypoxic region, leading to efficient tumor suppression by using phosphoglycerate kinase 1 (PGK1) silencing to enhance paclitaxel-induced chemotherapy and sensitize hypoxic GBM cells to ionizing radiation. In summary, a biomimetic intelligent RNAi nanomedicine has been developed for siRNA delivery to synergistically mediate a combined chemo/radiotherapy that presents immune-free and hypoxia-triggered properties with high survival rates for orthotopic GBM treatment.

Publisher

Research Square Platform LLC

Reference44 articles.

1. Stupp R, Hegi ME, Mason WP, Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet. Oncol. 10(2009) 459 – 66.

2. Buatti, First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma, Clin;Allen BG;Cancer Res,2019

3. Tannous, Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype;Teng J;Neuro Oncol,2018

4. Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines;Anderson JC;Radiother Oncol,2015

5. Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme;Angom RS;Oncogene,2020